3Seidman AD, Tiersten A, Hudis C, et al. Phase Ⅱ trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer [ J ]. J Clin Oncol, 1995,13 ( 10 ) :2575-2581.
4Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HEB2 [ J ]. N Engl J Med,2001,344( 11 ) :783-792.
5Robert N, Leyland-Jones B, Asmar L, et al. Phase Ⅲ comparative study of trastuzumab and paclitaxel with and without carbeplatin in patients with HER-2/neu positive advanced breast cancer[J]. Breast Cancer Res Treat,2002,76(supple) :37.
6Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplificanton[ J ]. J Clin Oncol,2001,19 (10) :2587-2595.
7Early Breast Cancer Trialists " Collaborative Group,Polychemotherapy for early breast cancer: an overview of the randomised trials [ J ]. Lancet, 1998,352 (2) :930-934.
8Henderson C, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer[ J ]. J Clin Oncol, 2003,21 ( 6 ) :976-983.
9Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741[J]. J Clin Oncol,2003,21 (8) :1431-1439.
